Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hutchison, R. E.
Right arrow Articles by Murphy, S. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hutchison, R. E.
Right arrow Articles by Murphy, S. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:S35-S38, 2000
© 2000 European Society for Medical Oncology

Symposium Articles

Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons

R. E. Hutchison1, C. Finch1, J. Kepner2, C. Fuller1, P. Bowman3, M. Link4, M. Schwenn5, J. Laver6, S. Desai7, D. Barrett1 and S. B. Murphy8

1 State University of New York Health Science Center Syracuse, NY, USA
2 Pediatric Oncology Group Statistical Office and the University of Florida Gainesville, FL, USA
3 Cook Children's Medical Center Ft. Worth, TX, USA
4 Stanford University Medical Center Palo Alto, CA, USA
5 University of Massachussetts Medical Center Worcester, MA, USA
6 Medical University of South Carolina Charleston, SC, USA
7 Cross Cancer Institute Edmonton, AB, USA
8 Children's Memorial Hospital, Northwestern University, and the Pedialric Oncology Group Chicago, IL, USA

Correspondence to: R. E. Hutchison, MD SUNY-Syracuse Health Science Center Pathology 750 E. Adams St. Syracuse, NY 13210 USA

Introduction: Burkitt-like lymphoma (BLL) is a provisional category of B-cell lymphoma which is morphologically intermediate between Burkitt lymphoma (BL) and large B-cell lymphoma (LBCL). The clinical significance of this morphology is controversial.

Patients and methods: We examined 41 cases of pediatric B-cell lymphoma by immunohistochemistry for proteins associated with proto-oncogenes c-myc, BCL-2 and BCL-6 and a subset of cases (with adequate slides) for a proliferation-associated marker (Ki-67) and for apoptosis (Apop-Tag). Sixteen cases of BLL, thirteen cases of BL and twelve cases of LBCL were examined.

Results: Our results showed BCL-6 expression in 16 of 16 BLL, 4 of 13 BL, and 9 of 12 LBCL; c-myc expression in 14 of 15 BLL, 9 of 13 BL, and 12 of 12 LBCL; and BCL-2 expression in 2 of 16 BLL, 0 of 13 BL, and 6 of 12 LBCL. Mean apoptotic index for BLL was 10.3% (n=6); for BL was 17.1% (n=5); and for LBCL was 10.9% (n=6). Ki-67 was diffusely reactive in all cases tested. There was a significantly higher proportion of BLL than BL which expressed BCL-6 (P=0.0001).

Conclusions: Labeling for BCL-6 distinguishes BLL from BL. It is likely that in children in North America, BLL is biologically distinct from BL and more closely resembles a subset of LBCL.

BCL-2, BCL-6, Burkitt lymphoma, Burkitt-like lymphoma, large B-cell lymphoma, non-Hodgkin's lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. M. Mead, M. R. Sydes, J. Walewski, A. Grigg, C. S. Hatton, P. Norbert, C. Guarnaccia, M. S. Lewis, J. McKendrick, S. P. Stenning, et al.
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study
Ann. Onc., August 1, 2002; 13(8): 1264 - 1274.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.